On July 6, Everest Medicines rose 7.05% in regular trading, trading at HK$29.78/share, with turnover of HK$111 million. The rally was driven by a confluence of intensive business development transactions and broad-based strength across the biotech sector.

The company has recently completed a series of high-profile BD deals, including licensing EVER001 global rights to Travere Therapeutics for a US$112.5 million upfront payment with up to US$1.03 billion in milestones, securing exclusive rights to Dimerix's kidney disease candidate DMX-200 in Greater China and parts of Asia, and acquiring LNZ100 commercialization rights from Jishi Pharma. Additionally, substantial shareholder CBC Group has accumulated over HK$172.5 million in open-market purchases since December, signaling strong insider conviction.

The broader biotech sector rallied in tandem, with Innovent Biologics up 7.0%, SKB Bio up 6.41%, and Remegen up 5.87%. Analyst coverage remains supportive, with CICC maintaining an Outperform rating and a target price of HK$41.5, implying approximately 48% upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)